



CURRICULUM VITAE

**PROF. PAROUNAK H. ZELVEIAN, MD, PH.D,
FESC**

Director of the Institute of Cardiology named L.A.
Hovhannisyan

Chief Cardiologist of Yerevan City

Past President of Armenian Cardiologist's Association

Past President of Armenian Medical Association

Paruyr Sevak St. 5, Yerevan 375044, Armenia

Tel: +374 (10) 288-606; +374 (10) 288-550

Fax: (+37410) 288-502

E-mail: zelveian@armeda.am or

zelveian@hotmail.com

www.cardio.am

Date and Place of Birth:	September 26, 1966, Yerevan, Republic of Armenia
Nationality:	Armenian
Citizenship:	Republic of Armenia
Sex:	Male
Education and Degrees:	
2007	European Society of Cardiology Educational Course: The everyday challenge of prevention, European Heart House, Sophia Antipolis Cedex, France.
2003	European Society of Hypertension Summer School, Ystad, Sweden.
2003	World Heart Federation's International Teaching Seminar on Cardiovascular Disease Epidemiology and Prevention, Pearson College of the Pacific, Victoria, British Columbia, Canada.
2002	American Heart Association's Hypertension Summer School, Williamsburg, VA, USA.
1997-2000	Fellow at the Department of Arterial Hypertension of the Institute of Clinical Cardiology of Cardiology Research Complex, Moscow, Russia. (Diploma of the Candidate of Medical Science (Ph.D) for the thesis: «Nocturnal profile of blood pressure and its peculiarity in mild to moderate essential hypertensives with sleep-disordered breathing», KT № 018621).
1993-1997	Residency at the Department of Arterial Hypertension of the Institute of Clinical Cardiology of Cardiology Research Complex, Moscow, Russia. Diploma of Doctorate of Cardiology Health with Honors, № 01-97.

1987-1993 Student of the Yerevan State Medical Institute after Mkhitar Heratsi, Yerevan, Armenia.
(Diploma of Doctoring of General Medicine (MD) with Honors, № 005574)

1973-1983 General school №67 after E. Charents, Yerevan, Armenia.
(Graduated with score 5/5)

Work experience:

2006-2013 Vice director of the Institute of Cardiology on Science

2013-2015 Director of the National Institute of Health

2015-2019 Director of the Center of Preventive Cardiology

2017-2019 Vice director of the Institute of Cardiology

2019 till now Director of the Institute of Cardiology

Awards and Scholarships:

1990-1993 M. Melik-Adamyanyan Scholarship for Academic Excellence, Yerevan, Armenia.

2000 1st prize and Honor Diploma as a «Best Young Scientist in Nomination Cardiology» in 7th Russian National Congress, Moscow, Russia.

2001 Honor Diploma, National Academy of Science of Republic of Armenia.

2001 Award after Edmond Keosayan (Honor Diploma), Yerevan, Armenia.

2003 Honor Diploma, Ministry of Health of Republic of Armenia.

2005 Honor Diploma, National Academy of Science of Republic of Armenia.

2006 Fellowship of European Society of Cardiology

Research activities:

Main research interests are related to hypertension, epidemiology and preventive cardiology and his current projects are focused on hypertension, ischemic heart disease, chronic heart failure and sleep breathing disorders.

Principal Investigator in several multicenter II-IV phase studies and National Coordinator of «MHM», «SIGNIFY», «QUALITY», «QUALIFY», «TRIPLE-A», «REALITY», «MMM-17», «TELE-REMETRI», «MMM-18», «MMM-19», «ESH BP CONTROL», «PRECIOUS» and other studies.

Reviewer for a number of national and international peer-reviewed journals, member of several national and international journals Editorial Board.

Currently Chief Editor of the Scientific Medical Journal of the National Institute of Health of the Ministry of Health of the Republic of Armenia.

Books and/or chapters: 22

Publications: Articles: 158
(listed until January 2020) Abstracts: 267

Membership in Professional Organizations: Armenian Medical Association (Founder and Past President);
Armenian Cardiologists Association (Past President);
Armenian Society on Hypertension (The President);
Eurasian Cardiologists Association (Board Member);
European Society of Cardiology (Fellow);
European Association for Cardiovascular Prevention & Rehabilitation (National Coordinator);
International Society of Hypertension;
European Society of Hypertension;
American Society of Hypertension;
American Heart Association (Council for High Blood Pressure Research);
European Sleep Research Society;
American Academy of Sleep Medicine;
World Association of Sleep Medicine.

Languages: Native language Armenian, fluent in Russian and English.


Interests: Classical and Jazz music, theater, literature.

EXPERIENCE IN CLINICAL TRIALS:

Year trial started	Indication of the trial	Clinical Phase (I-IV)	Completed	On-going
2008	Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo on top of a background therapy with a calcium antagonist (amlodipine or nifedipine) in patients with stable angina pectoris. A 6-week randomised double-blind parallel-group international multicentre study. Principal Investigator.	III	<input checked="" type="checkbox"/>	<input type="checkbox"/>
2010	Bioequivalence study of Enalozid® Forte (Enalapril + Hydrochlorothiazide) tablet («Farmak», JSCY) and Co-renitec ® (Enalapril + Hydrochlorothiazide) tablet («Merck Sharp & Dohme B.V.») in healthy, adult volunteers. Principal Investigator.	I	<input checked="" type="checkbox"/>	<input type="checkbox"/>
2010	Bioequivalence study of Ursomaks 250 mg capsule («Farmak», JSCY) and Ursofalk® 250 mg capsule («Dr. FALK PHARMA», GmbH) in healthy, adult volunteers. Principal Investigator.	I	<input checked="" type="checkbox"/>	<input type="checkbox"/>

2011	Randomized, Double-Blind, Multi-center Study Comparing 15 g Cross-linked Polyelectrolyte (CLP) versus Placebo in Heart Failure Patients with Chronic Kidney Disease. Principal Investigator.	II	<input checked="" type="checkbox"/>	<input type="checkbox"/>
2012	A pilot bioequivalence study of Hydrochlorothiazide 12.5 mg capsule (Lannett Company Inc.) and Microzide 12.5 mg capsule (Watson Labs) in 12 healthy, adult subjects under fasting conditions. Principal Investigator.	II	<input checked="" type="checkbox"/>	<input type="checkbox"/>
2011	Effects of Ivabradine in patients with stable coronary artery disease without clinical heart failure. A randomised double-blind Placebo-controlled international multicentre study. Study assessInG the morbi-mortality beNefits of the If inhibitor Ivabradine in patients with coronary arterY disease (SIGNIFY). National Coordinator. Principal Investigator.	III	<input checked="" type="checkbox"/>	<input type="checkbox"/>
2015	Safety and efficacy of fixed dose combination of Indapamide SR/Amlodipine in single-pill versus free dual therapy at the same dose over 12-week of treatment, with conditional titration based on the blood pressure control, in patients with mild to moderate uncontrolled essential hypertension. An international, multicentre, randomised, open-label study. National Coordinator. Principal Investigator.	III	<input checked="" type="checkbox"/>	<input type="checkbox"/>
2016	Losartan (Lorista®) and Fixed-Dose Combination of losartan and hydrochlorothiazide (Lorista® H, Lorista® H100, Lorista® HD) – its efficacy, safety and influence on metabolic parameters in hypertensive patients. Principal Investigator.	IV	<input checked="" type="checkbox"/>	<input type="checkbox"/>
2019	Fixed-Dose Combination of Perindopril/ Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) – Contribution to Management in newly diagnosed and uncontrolled hypertensive patients (PRECIOUSS study). Interventional, open-label, prospective, international, multi-centre clinical trial. National Coordinator. Principal Investigator.	IV	<input checked="" type="checkbox"/>	<input type="checkbox"/>

2020	Clinical validation of the brachial blood pressure measuring device Withings BPM Connect according to “the Universal Standard for the validation of blood pressure measuring devices by the Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO)” in the pregnant population. National Coordinator. Principal Investigator.	IV	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2020	NATriuretic Response to expansion and diUretics in huMans with Heart Failure (NATRIUM-HF). National Coordinator. Principal Investigator.	IV	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2020	Clinical validation of the brachial blood pressure measuring device Withings BPM Connect according to “the Universal Standard for the validation of blood pressure measuring devices by the Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO)” in the general population. National Coordinator. Principal Investigator.	IV	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2020	Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis. Principal Investigator.	III	<input type="checkbox"/>	<input checked="" type="checkbox"/>



19 September 2021